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Introduction
Hepatitis B virus (HBV), which belongs to the family 
of Hepadnaviridae and is one of the smallest enveloped 
DNA viruses, is a global health concern as more than 
2 billion of people are affected and around 260 million 
of people are chronically infected. In 2015, according 
to WHO, 275 million people live with HBV, and as 
estimated, 887 000 deceased as a result of the infection 
(WHO 2019). The virus is very old, as it has been infect-
ing humans for at least 28 centuries. Humans are the 
only reservoir for this pathogen, which is 50–100 times 
more contagious than the Human Immunodeficiency 
Virus (Cheah et al. 2018). Both morbidity and mortal-
ity rates are high, as there is an increased lifetime risk 
of hepatocellular carcinoma, cirrhosis and liver disease 
(Bissinger et al. 2015; Cheah et al. 2018; Kostaki et al. 
2018). Due to error-prone reverse transcriptase activity, 
a high nucleotide mismatch rate (105 change/base/repli-
cation) and a high replicative capacity (> 1012 virion/day) 
are observed, and HBV is characterized by a significant 
degree of genetic heterogeneity (Kostaki et al. 2018). The 
HBV genome encloses four partially overlapping open 
reading frames, which are PreS1/S2/S, PreC/C, P, and 
X encoding seven different proteins. Most significantly, 
Reverse Transcriptase (RT) and HBsAg frames overlap 
at RT amino acid 8–236, with HBsAg frameshift down-
stream by one nucleotide. Therefore, it indicates that 
mutations in these specific areas might result in drug 
resistance (Zehender et al. 2014; Zamor et al. 2017).
The high degree of genomic heterogeneity catego-
rizes HBV into 10 genotypes (A-J), and an intergroup 
difference of around 7.5% is observed. All genotypes, 
except E and G, are classified further into 25 different 
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A b s t r a c t
There is an increased demand for molecular and epidemiological information regarding Hepatitis B Virus (HBV) infection as the disease 
severity depends on these specifications. We have aimed to analyze nucleos(t)ide analogues (NA) resistance and typical HBsAg escape 
mutations with the dispersion of HBV genotype/subgenotype/HBsAg serotypes on overlapping pol/S gene regions in the Turkish popula-
tion. Samples were collected in Northern Cyprus. Reverse transcriptase (rt) region between 80–250 amino acids were amplified. Typical 
HBsAg escape mutations were determined as HBIg escape (6.48%), vaccine escape (8.34%), HBsAg misdiagnosis (9.25%), and immune 
escape mutations (8.34%). NAs resistances were determined as primary (2.78%), partial (2.78%), and compensatory mutations (26.85%) 
in overlapping pol/S gene region. The study patients were predominantly infected with HBV genotype D/D1 (98%). However, the pre-
dominant HBsAg serotype was ayw2 (99%). The most common NA resistance mutation was rtQ215H/P/S (16.67%), however, for S gene 
the misdiagnosis mutations were observed most frequently (9.25%). We can conclude that HBV D/D1 is the dominant strain and ayw2 is 
the dominant serotype in the Turkish Cypriot. Cyprus is an island located in the Eastern Mediterranean region, and it is, therefore, a key 
location for human trafficking and immigration; as a result of this reputation, it is necessary to analyze HBV phylogenetically for local 
dynamics, and our results indicate that treatment naïve population is prone to these pol/S gene mutations. However, if HBV strains were 
also analyzed among Greek Cypriots too, this would enable a complete island survey. With this work, we believe that we have enlightened 
this subject for further research.
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subgenotypes, with a difference of around 4% being 
observed (Kramvis et al. 2005; Kostaki et al. 2018). 
HBV-A and HBV-D are present around the globe, 
whereas HBV-A is mainly seen in Europe and Africa, 
and HBV-D in the Middle East and Europe. HBV-B 
and HBV-C are generally found in Oceania and Eastern 
Asia, HBV-E in both Central and Western Africa. HBV- 
F and HBV-H are found in Alaska and Latin America 
only. HBV-D is considered to be pandemic. HBV-D1 
is dominant in Australia, Europe, Indonesia, North 
Africa, and Western Asia, whereas HBV-D2 is seen in 
Albania, Japan, Malaysia, North-Eastern Europe, Rus-
sia, and United Kingdom (Tallo et al. 2008; Bissinger 
et al. 2015; Kostaki et al. 2018). A recent study in Brazil 
showed that due to Italian colonization, the dominance 
of genotype D/D3 is observed (Paoli et al. 2018). A sim-
ilar study was performed before in the same region, and 
once again, genotype D/D3 was found to be the most 
relevant genotype (Chacha et al. 2017).
The prevalence of HBV can be classified into three 
regions; low (< 2%), middle (2–7%), and high (> 8%) 
endemities. Turkey is categorized as middle endemicity 
with a prevalence rate of 0.8–5.7%, while the Turkish 
Republic of Northern Cyprus (TRNC) falls into a low 
category with a rate of 1.2% (Arikan et al. 2016; Ozguler 
and Sayan 2018). However, Cyprus is an island located 
in the Eastern Mediterranean, to the south of Turkey. 
Since 1974, there have been two communities living 
separately on the island: Turkish and Greek Cypriots. 
The exact population of North Cyprus is not known as 
the population number is dynamic, this is due to sex 
worker and immigrant trafficking that occurs along 
with constant international student and tourist travel. 
However, there is no data regarding HBV dynamics for 
South Cyprus. The South of the island is subject to more 
immigrations and human trafficking (Kaptanoglu et al. 
2013; U.S. Department of State Publication 2018).
Cyprus had an estimated population of 1 193 635 in 
2011. Around 352 000 were believed to live in North 
Cyprus, but the number has climbed up to half a mil-
lion. Half of these are Cypriot-born children or Turk-
ish settlers. Around 230 000 of those are classified as 
native-born TRNC citizens. The exact population 
remains unknown as North Cyprus has a  dynamic 
society of students and tourists who regularly visit the 
island (Christou 2018; World Population Review 2018). 
Immunisation against HBV in the TRNC was rare in 
the late 80s, and the program was first introduced in 
the country in July 1998 (Kurugol et al. 2009). Between 
2014 and 2018, 3149 HBsAg positive Turkish citizens 
were living in the TRNC, where 98.16% were of Turkish 
origin and 1.84% was Turkish Cypriots (KKTC Sağlık 
Bakanlığı 2019). Previous studies have concluded that 
the overall HBsAg positivity rate for the TRNC is 1.2% 
(Arikan et al. 2016).
There is a high demand for genotype information 
and investigation regarding HBV infected individu-
als. This importance rules to be informed regarding 
molecular and epidemiological specifications. As with 
the aim of this importance, we have aimed to analyze 
the dispersion of genotype/subgenotype/serotype 
together with pol gene mutations, which are related to 
NA therapy, and S gene mutations.
Experimental
Materials and Methods
Patients Samples. HBsAg reactive serum samples 
were collected and stored at –80°C in the Near East 
University Laboratory, Nicosia and Lancet Medi-
cal Diagnostic Laboratory, Famagusta between the 
dates of January 2015 and August 2018. This project 
obtained the Ethical Committee approval on 29 March 
2018 from the Near East University Ethical Commit-
tee (Approval Number YDU/2018/56-539). As part of 
the Ethical approval, Helsinki Declaration principles 
were followed. Samples were taken from patients who 
presented to either of the health centers for residential 
permit screening, pre/post-operation screening, blood 
bank screening, and privately requested tests. The total 
number of samples in our study (n = 170) represented 
the total number of HBsAg reactive diagnoses made 
between the dates of January 2015 and August 2018. 
Unfortunately, information on the HBV infection status 
or phase of the patients is not available as they were not 
follow-up patients.
Serological Analysis. These samples were all scree-
ned for Anti-HCV, HBsAg, HIV Ag/Ab and Syphilis 
TP using Abbott Architect i1000SR/i2000SR automated 
analyzers. Out of the samples, only Turkish and Turkish 
Cypriot samples were selected (n = 170). Only HBsAg 
levels of the samples were measured primarily, and 
no other Hepatitis B serological markers were studied 
(such as AntiHBc).
Genotyping, subgenotyping, serotyping and 
muta tion analysis. Out of 170 samples, only 108 were 
sequenced, as rest of the samples did not yield any HBV 
DNA load. The clinical demographics of the samples 
are given in Table I. For HBV genotypes/subgenotypes, 
nucleos(t)ide analogue (NA) drug resistance analysis, 
and S gene analysis the overlapping the Pol/S gene 
region (rt region, between amino acids 80–250) were 
chosen. For HBV pol gene ampliﬁcation (742 base 
pairs), forward (F: 5’-TCGTGGTGGAC TTCTCTCA 
ATT-3’) and backward (R: 5’-CGTTGACAGAC TTTC 
CAATCAAT-3’) primers were designed and used. HBV 
Pol gene amplification and Sanger dideoxy sequencing 
protocols were all performed as described previously 
by Sayan et al. (2010).
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Sequences obtained were subsequently analyzed 
using a special online tool, the Geno2pheno (Centre 
of Advanced European Studies and Research, Bonn, 
Germany) drug resistance platform. The following tar-
get region and amino acid positions were analyzed for 
the determination of antiviral drug-associated potential 
vaccine-escape mutations (ADAPVEM) regions 161, 
164, 172, 173, 175, 176, 182, and 193–196; HBIg selected 
escape mutation regions 118, 120, 123, 124, 129, 133, 
134, 144, and 145; vaccine escape mutation regions 120, 
126, 133, 143–145, and 193; Hepatits B misdiagnosis 
mutation regions 120, 131, 133, and 143; immune-
selected mutation regions 100, 101, 105, 109, 110, 114, 
117, 119, 120, 123, 127, 128, 130–134, 140, and 143–
145. The target region and amino acid position for the 
determination of HBV pol gene mutation were as fol-
lows: overlapping surface gene segments 100, 101, 105, 
109, 110, 114, 117–121, 123, 124, 126, 127, 128–135, 
137, 139, 140–142, 144–149, 151–153, 155–157, 161, 
172, 173, 175, 176, and 193–196. The following target 
region and amino acid position for the determination 
of HBV pol gene mutation were analyzed: rt gene seg-
ments 74, 80, 82, 84, 85, 139, 149, 156, 169, 173, 180, 
181, 184, 194, 200, 202, 204, 214, 215, 233, 236, 237, 
238, and 250 (Sayan et al. 2012; Asan et al. 2018).
HBV genotype/subgenotypes were also phylogeneti-
cally analyzed using the Neighbour-Joining method. Pri-
marily, the sample sequences and reference sequences 
were all aligned. A phylogenetic tree was created using 
CLC Sequence Viewer 8.0 (CLC bio A/S, Qiagen, Den-
mark). A bootstrap value of 1000 was chosen.
Three HBsAg glycoproteins share an a determinant 
epitope, which is located at the position 127–147. There 
are two other determinants namely, d/y at the position 
122, lysine/arginine residue and w/r at the position 
160; lysine/arginine residue represents each determi-
nant, respectively. At the position 127, residue further 
differentiates w into four subtypes. The adr subtype 
only is further divided into q–/q+. With these com-
binations, nine different subtypes of HBV have been 
identified (Yokosuka and Arai 2006). The analysis of 
HBsAg serotypes was also performed using the CLC 
sequence viewer, as the geno2pheno tool is not able to 
detect this information. After aligning the sequences 
to reference sequences, the phylogenetic parameters of 
UPGMA/Jukes-Cantor were used and the bootstrap 
value of 1000 was used.
Results
Baseline data. Out of 170 samples included in the 
study, only 108 (63.5%) were sequenced. Demographic 
characteristics of the patients from whom these sam-
ples were collected are listed in Table  I. Genotypes/
subgeno types/HBsAg serotype analysis of 108 samples 
were performed following aligning for phylogenetic 
analysis (Fig. 1 and 2).
RT mutations. NA resistance mutations were 
detected in 35/108 (32.4%) of the samples, and as 
a  novel data 2/108 (1.85%) of these samples confer 
ADAPVEMs (Table II). The compensatory resistance 
pol gene mutations were the most frequent as 29/108 
(26.85%) of the samples comprise this category, fol-
lowed by primary resistance mutations in 3/108 
(2.78%), and lastly, partial resistance mutations in 3/108 
(2.78%) samples analyzed. The most prevalent pol gene 
mutation was rtQ215H/P/S and it falls in the compen-
satory mutation category.
The S gene mutations. A total of 17/108 (15.74%) 
the S gene mutations were detected, together with 3/108 
(2.78%) combined escape mutations in the same region 
(Table III). The highest S gene escape mutations were 
detected for HBsAg misdiagnosis 10/108 (9.25%), both 
vaccine and immune escape mutations in 9/108 (8.34%), 
and the lowest number mutations were observed for 
HBIg escape with a frequency of 6.48% (7/108).
Genotyping, subgenotyping and serotyping. 
According to our results, HBV-D/D1 was observed to 
be the major genotype/subgenotype with a prevalence 
of 106/108 (98%), and ayw2 was the major serotype 
that accomplishes 99% (96/108 ) in Turkish Cypri-
ots (Table IV). Also, it is important to mention that 
only 1/108 (1%) Turkish Cypriot were infected with 
HBV-D/D2, and 1/108 (1%) Turkish citizen were 
infected with HBV-E. A significant finding is that 
HBV-D/D2 was the only ayw3 serotype 1/108 (1%).
Discussion
In our former research the following HBV geno-
types were found, namely: D/D1; 70.6%, D/D2; 5.9%, 
D/D3; 1.5%, A/A1; 7.4%, A/A2; 2.9%, and E; 11.8% 
(Sayıner and Abacıoglu 2010; Arikan et al. 2016). 
However, in this study, D/D1 was found in 98% of the 
Patients, n 170 108
Gender, M/F, n (%) 106 (63) / 64 (37) 68 (63) / 40 (37)
Age, years (mean ± SD) 49 ± 31 41.5 ± 23.5
Nationality Turkish 122 (71) 83 (77)
Turkish Cypriot 48 (29) 25 (23)
HBsAg value, S/Co*
(mean ± SD) 
3882.5 ± 3712.5 3882.5 ± 3712.5
Table I
Demographic characteristics of the patients.
Abbreviations: M – male; F – female; *S/Co: Sample/Cut-off.
HBsAg value was obtained using Abbott Architect i1000SR/i2000SR 
systems (Abbott, USA).
Characteristics Patient group Study group
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samples, and D/D2 and E only in 1% of the samples 
examined, respectively (Table IV). The most often 
detected genotype was D/D1 for both patient groups. 
This is the only similarity with our previous works 
and the main dissimilarity we observed in this study 
was that D/D2 was found in a Turkish Cypriot, and 
Fig. 1. Circular cladogram of HBV genotypes and subgenotypes. The phylogenetic tree was constructed using the CLC sequence viewer 
(CLC bio A/S, Qiagen, Denmark). The HBV reverse transcriptase region length was 495 base pairs in the alignment. The Neighbour-
Joining and Jukes-Cantor methods were used. The Bootstrap value was chosen as 1000. HBV genotype A: KY886219.1, B: FJ562300.1, 
C: FJ023667 D: KP997995, D/D1: LC365689.1, D/D2:GU456635.1, E: KF922438.1, F: KY458062, G: KX264500.1, H: KX264501.1, I: 
GU357844.1 reference sequences were obtained from GenBank.
a Turkish person was found to have genotype E, which 
has not been previously observed (Arikan et al. 2016).
Regarding other than Mediterranean region, high 
rates of genotype D have also been observed in the Mid-
dle East, South Asia, and North-East Europe (Sunbul 
et al. 2014; Zehender et al. 2014). Our results support 
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these regions, while other genotypes such as the sero-
type E could also be observed in the future (Zehender 
et al. 2014). In 2018, the article by Velkov et al. (2018) 
has been published that presents the global genotype 
distribution of HBV, assessing 125 countries and over 
Fig. 2. Circular cladogram of HBsAg serotypes. The phylogenetic tree was constructed using the CLC sequence viewer (CLC bio A/S, 
Qiagen, Denmark). The HBV reverse transcriptase region length was 495 base pairs in the alignment. The UPGMA and Jukes-Cantor 
methods were used. The Bootstrap value was chosen as 1000. HBV D Serotype ayw1: AY576433, ayw2: KT749854.1, ayw3: FJ349218.1, 
ayw4: FJ349207.1 reference sequences were obtained from GenBank.
these findings as the majority of the students, sex work-
ers, and labor workers mostly travel and immigrate to 
the TRNC from Europe, Turkey, and Africa. Therefore, 
we can state that genotype D was introduced into the 
society via migrations in the past several decades from 
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900 publications. Their findings indicated that genotype 
D was dominant in Eastern Europe, the majority of Asia 
and North Africa. HBV genotype distribution shows 
a  similar pattern among the countries in the same 
region but varies amongst different parts of the world.
Large population migrations can modify public 
health dynamics. High frequency of genotypes A-D was 
observed in North America following migrations from 
Asia and Europe. A similar situation was observed in 
the Caribbean where genotypes A and D were found as 
a result of migrations from the African continent (Velkov 
et al. 2018; Al-Sadeq et al. 2019). We can see that migra-
tions mainly from Turkey for working and living, and 
other parts of the Middle East for other purposes such 
HBIg escape sP120T, sQ129H, sM133I, sY134N, sD144E, sC147S  7 (6.48) sM133I + sD144E 1 (0.92)
Vaccine escape sP120S, sQ129H, sS143L, sD144E, sC147S, sS193L  9 (8.34) sT126S + sS193L 1 (0.92)
HBsAg misdiagnosis sP120T, sP120S, sR122K, sT131I, sM133I, sC147S 10 (9.25)     –   –
Immune escape sQ101H, sG119R, sP120T, sT123N, sT131N, sY134F, sD144E  9 (8.34) sG119R + sT123N 1 (0.92)
Total* – 17 (15.74)     – 3 (2.78)
Table III
HBsAg escape mutations in the study patients.
* The total number of patients which HBsAg mutation was detected.
HBsAg escape
mutation category Mutation pattern
Patient,
n (%)
Combined
pattern
Patient,
n (%)
D
 D1 106 (98) ayw2, 96 (99) TR, TRNC
 D2   1 (1) ayw3, 1 (1) TRNC
E –   1 (1) – TR
Total – 108 (100) 97 (100) –
Table IV
HBV genotypes, subgenotypes, and HBsAg serotypes of the samples.
Abbreviations: TR – Turkey, TRNC – Turkish Republic of Northern Cyprus.
*Genotype E strain and short sequences (n = 11) were not included in serotype analysis.
HBV
genotype
HBV
subgenotype
Patients,
n (%)
HBsAg serotype,
n (%)* Nationality
Primary resistance mutation rtM204I LAM, LDT, L-FMAU, FTC  2 (1.85)
 rtI233V ADV  1 (0.92)
Total* – –  3 (2.78)
Partial resistance mutation rtL80I LAM, LDT  1 (0.92)
 rtL180M LAM, LDT, L–FMAU, FTC  2 (1.85)
Total* – –  3 (2.78)
Compensatory mutation rtL91I LDT  7 (6.48)
 rtQ149K ADV  7 (6.48)
 rtV214A LAM, L-FMAU, FTC, TDF  2 (1.85)
 rtQ215H/P/S LAM, L-FMAU, FTC, TDF 18 (16.67)
 rtN238D ADV  6 (5.56)
Total* – – 29 (26.85)
ADAPVEM rtM204I/sW196L LAM, LDT  2 (1.85)
Total* – –  2 (1.85)
Table II
HBV pol gene mutation pattern and frequency in the study patients.
Abbreviations: LAM – lamivudine; LDT – telbivudine; L-FMAU – clevudine; FTC – emtricitabine; 
 TDF – tenofovir; ADV – adefovir; ETV – entecavir;
 ADAPVEM – antiviral drug-associated potential vaccine escape mutant.
*Total: the number of total included rt gene mutations in 108 sequenced samples. The aa position 250 is where 
we expect a specific mutation to occur, two unknown mutations rtM250G/H detected were ETV related 
amino acid substitutions; these are not mutations which cause nucleostide resistance.
Mutation characteristic Mutation pattern Nucleos(t)ide analogue Patient, n (%)
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as studying have caused genotype D to be dominant and 
new genotypes such as E introduced to the TRNC.
In this study, a total of 3/108 (2.78%) primary, 3/108 
(2.78%) partial and 29/108 (26.85%) compensatory 
mutations were observed in the rt gene (Table II). How-
ever, previously, primary/partial resistance mutations 
occurred with a frequency of 1% and compensatory 
mutations were of 37% (Arikan 2015). When analyzed 
in greater details, rtM204I, rtI233V, rtL80I, and rtL180M 
mutations were not detected before, and these muta-
tions, particularly rtL80I and rtL180M, restore the activ-
ity of viral polymerase to near wild type levels, which 
helps to promote the replication of mutants (Lazarevic 
2014). This indicates that treatment naïve population is 
prone to such mutations, and has a significant impact 
on the treatment procedures and costs. Also, primary/
compensatory mutations alone may increase HBV DNA 
levels and cause failure in future treatment (Sayan 2010; 
Sayan et al. 2010; Sayan et al. 2011).
The S gene mutations; however, indicate different 
structure when compared to earlier work. In our study, 
the total number of the S gene mutations was 17/108 
(15.74%), and combined S gene mutations were 3/108 
(2.78%) (Table III). The previous work revealed the fre-
quency of 29% and 9%, respectively (Arikan et al. 2016). 
HBIg selected escape mutations in former work was 
6%; however, in this study, different mutation pattern 
is observed with a similar percentage of 7/108 (6.48%); 
(Table III) (Arikan et al. 2016). sQ129H, sM133I, and 
sY134N mutations are associated with occult infection 
with D genotype; also they impair S protein secretion 
(Lazarevic 2014). HBV vaccine escape mutations in 
the prior work were observed with the frequency of 
10% (Arikan et al. 2016). In this study, it was observed 
in 9/108 (8.34%) of the samples analyzed (Table III). 
Hepatitis B misdiagnosis mutation patterns in earlier 
work were only 4%, whereas in this study it was higher, 
and accounted for 9.25% (10/108) (Table  III). Lastly, 
immune escape mutations in previous work were as 
often as in 24% of the samples. On the other hand, in 
this study, only 9/108 (8.34%) samples carried these 
mutations (Table III) (Arikan et al. 2016). Combined 
HBsAg mutations in this research were dissimilar to 
earlier study as 9% of the samples had such mutations, 
but in this study only 3/108 (2.78%) samples carried 
them (Arikan 2015). In summary, S gene mutations 
may lead to misdiagnoses (false-negative results) and 
cause insufficient protection using HBIg.
In the study by Al-Sadeq et al. (2019) performed in 
the Middle East and North Africa region, S gene muta-
tions were detected in Egyptian, Saudi, Palestinian and 
Tunisian patients, in whom the genotypes B, D/D1, 
D/D3, and D/D7 were identified. We have detected only 
five common mutations and all the S gene mutations 
were observed only in D/D1 patients (Table III). This 
indicates that different geographical regions may have 
different S gene mutation profiles, even though the 
genotypes of the patients are the same. The ADAPVEM 
analysis revealed 2/108 (1.85%) of the samples carried 
such mutations. These were rtM204I/sW196L muta-
tions (Table II). In Turkey, the same mutation pattern 
was observed in 8.7% of the patients together with other 
ADAPVEMs. The ADAPVEM status has not yet been 
known for the TRNC, these results are initial data for 
monitoring of such mutations in the future. (Sayan et al. 
2013; Asan et al. 2018; Ozguler and Sayan 2018).
In conclusion, HBV-D/D1 was the dominant strain, 
and ayw2 is the serotype most often detected among 
Turkish Cypriots. Cyprus is an island located in the 
Eastern Mediterranean region, a strategic location for 
human trafficking and immigration, and as a result of 
this reputation, it is necessary to analyze HBV phyloge-
netically for international and local importance. How-
ever, data from Greek Cypriot is necessary, as it would 
enable a complete island survey to be performed. With 
this work, we believe that we have set the ground for 
further research of this topic.
One of the limitations of this study is a sample 
size, as larger samples will generate more significant 
results. The lack of prior work is another limitation as 
there is only one previous study, and additional work 
will uncover significant results in the future. Another 
limitation is that information is not available about the 
HBV infection status or phase of the patients as they 
were not follow-up patients.
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